8 results on '"Ozbek U"'
Search Results
2. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
- Author
-
Van Der Velden, V H J, Cayuela, J-M, McCarron, S, Sacha, T, Fletcher, L, Ziermann, J, Müller, M C, Schimmel, H, El Housni, H, White, H, Farrugia, J, Boeckx, N, Romeo, G, Johnels, P, Zoi, K, Chudleigh, S, Lion, T, Kairisto, V, Deprez, L, Ganderton, R, Merle, P A, Dulucq, S, Pajič, T, Gerrard, G, Martinelli, G, Trapmann, S, Hall, V, Nagar, M, Colomer, D, Hochhaus, A, Kizilors, A, Mitterbauer-Hohendanner, G, Talmaci, R, Gineikienė, E, Oppliger Leibundgut, Elisabeth, Mazoua, S, Cross, N C P, Milner, B, Zadro, R, Lin, F, Foroni, L, Waits, P, Kim, D-W, Nickless, G, Jansson, M, Pfeifer, H, Wilson, G, Raudsepp, K, Clench, T, Daraio, F, Preudhomme, C, Wang, L, Emons, H, Bench, A, Nomdedéu, J, Wilkinson, E, Hayette, S, Jurcek, T, Aggerholm, A, Izzo, B, Lange, T, Akiki, S, Andrikovics, H, Polakova, K M, Corbisier, P, Ozbek, U, Nymoen, D A, Wren, D, Barbany, G, Catherwood, M, and Touloumenidou, T
- Subjects
hemic and lymphatic diseases ,610 Medicine & health ,3. Good health - Abstract
Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10(6), 1.08±0.11 × 10(5), 1.03±0.10 × 10(4), 1.02±0.09 × 10(3), 1.04±0.10 × 10(2) and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).
3. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
- Author
-
J M Cayuela, BJ Milner, Stéphane Mazoua, Elisabeth Oppliger Leibundgut, Linda Fletcher, Heike Pfeifer, Tomáš Jurček, E Gineikienė, P. Waits, Susanna Akiki, G Wilson, J Farrugia, H El Housni, Ugur Ozbek, D Wren, F. Lin, Tomasz Sacha, Hajnalka Andrikovics, S Chudleigh, Letizia Foroni, Stefanie Trapmann, Petra Johnels, Gareth Gerrard, Thomas Lion, M. Jansson, Katerina Zoi, Hendrik Emons, K. Raudsepp, Gisela Barbany, D A Nymoen, H Schimmel, J Ziermann, Nancy Boeckx, Mark Catherwood, Sandrine Hayette, G Romeo, Helen E. White, R Ganderton, Filomena Daraio, G. Mitterbauer-Hohendanner, Philippe Corbisier, Claude Preudhomme, Andreas Hochhaus, Martin C. Müller, P A Merle, V H J van der Velden, M Nagar, Victoria J. Hall, Lihui Wang, Theis Lange, Tim Clench, T Pajič, Stéphanie Dulucq, D-W Kim, Nicholas C.P. Cross, Josep F. Nomdedeu, Rodica Talmaci, Kateřina Machová Poláková, A Bench, Liesbet Deprez, T Touloumenidou, G Nickless, Veli Kairisto, Barbara Izzo, Dolors Colomer, Aytug Kizilors, Giovanni Martinelli, Renata Zadro, Anni Aggerholm, S McCarron, E Wilkinson, Hematology, CCA - Disease profiling, White, H, Deprez, L, Corbisier, P, Hall, V, Lin, F, Mazoua, S, Trapmann, S, Aggerholm, A, Andrikovics, H, Akiki, S, Barbany, G, Boeckx, N, Bench, A, Catherwood, M, Cayuela, Jm, Chudleigh, S, Clench, T, Colomer, D, Daraio, F, Dulucq, S, Farrugia, J, Fletcher, L, Foroni, L, Ganderton, R, Gerrard, G, Gineikienė, E, Hayette, S, El Housni, H, Izzo, Barbara, Jansson, M, Johnels, P, Jurcek, T, Kairisto, V, Kizilors, A, Kim, Dw, Lange, T, Lion, T, Polakova, Km, Martinelli, G, Mccarron, S, Merle, Pa, Milner, B, Mitterbauer Hohendanner, G, Nagar, M, Nickless, G, Nomdedéu, J, Nymoen, Da, Leibundgut, Eo, Ozbek, U, Pajič, T, Pfeifer, H, Preudhomme, C, Raudsepp, K, Romeo, G, Sacha, T, Talmaci, R, Touloumenidou, T, Van der Velden, Vh, Waits, P, Wang, L, Wilkinson, E, Wilson, G, Wren, D, Zadro, R, Ziermann, J, Zoi, K, Müller, Mc, Hochhaus, A, Schimmel, H, Cross, Nc, Emons, H., Immunology, Radiology & Nuclear Medicine, Izzo, B, and Mitterbauer-Hohendanner, G
- Subjects
EMTREE drug terms: plasmid DNA EMTREE medical terms: Article ,Cancer Research ,Fusion Proteins, bcr-abl ,Gene Dosage ,Membrane Transport Protein ,Plasmid ,RECOMMENDATIONS ,real time quantitative polymerase chain reaction ,K562 cell line ,law.invention ,law ,hemic and lymphatic diseases ,Escherichia coli Protein ,CANCER PROGRAM ,Digital polymerase chain reaction ,Cloning, Molecular ,Polymerase chain reaction ,MOLECULAR RESPONSE ,Medicine (all) ,Escherichia coli Proteins ,copy number variation ,breakpoint cluster region ,gene control ,Hematology ,Reference Standards ,gusb gene ,3. Good health ,Real-time polymerase chain reaction ,Certified reference materials ,priority journal ,Oncology ,real time polymerase chain reaction ,Calibration ,Proto-Oncogene Proteins c-bcr ,Original Article ,Life Sciences & Biomedicine ,Medical Genetics ,Plasmids ,EUROPE ,POLYMERASE-CHAIN-REACTION ,610 Medicine & health ,Biology ,Real-Time Polymerase Chain Reaction ,IMATINIB ,Gene dosage ,Anesthésiologie ,chronic myeloid leukemia ,TRANSCRIPTS ,TYROSINE KINASE INHIBITORS ,bcr abl gene ,Humans ,controlled study ,human ,ddc:610 ,RNA, Messenger ,CHRONIC MYELOID-LEUKEMIA ,gene ,certified plasmid reference material ,bcr-abl1 ,Medicinsk genetik ,freeze thawing ,Messenger RNA ,Science & Technology ,human cell ,reference value ,Membrane Transport Proteins ,HL 60 cell line ,DNA ,ta3122 ,Molecular biology ,Cancérologie ,Anesthesiology and Pain Medicine ,certified reference material ,minimal residual disease ,Reference Standard ,Hématologie - Abstract
Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10 6, 1.08±0.11 × 10 5, 1.03±0.10 × 10 4, 1.02±0.09 × 10 3, 1.04±0.10 × 10 2 and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f)., 0, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2015
4. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
- Author
-
Turan RD, Tastan C, Dilek Kancagi D, Yurtsever B, Sir Karakus G, Ozer S, Abanuz S, Cakirsoy D, Tumentemur G, Demir S, Seyis U, Kuzay R, Elek M, Kocaoglu ME, Ertop G, Arbak S, Acikel Elmas M, Hemsinlioglu C, Hatirnaz Ng O, Akyoney S, Sahin I, Kayhan CK, Tokat F, Akpinar G, Kasap M, Kocagoz AS, Ozbek U, Telci D, Sahin F, Yalcin K, Ratip S, Ince U, and Ovali E
- Subjects
- Angiotensin-Converting Enzyme 2 genetics, Angiotensin-Converting Enzyme 2 metabolism, Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Chlorocebus aethiops, Cytokines metabolism, Dose-Response Relationship, Immunologic, Gamma Rays, Humans, Immunity, Lung pathology, Mice, Mice, Inbred BALB C, Mice, Transgenic, RNA, Viral, SARS-CoV-2 radiation effects, Vaccination, Vaccines, Inactivated immunology, Vero Cells, Virus Replication, COVID-19 prevention & control, COVID-19 Vaccines immunology, SARS-CoV-2 immunology
- Abstract
The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma-irradiated inactivated virus vaccine does not require an extra purification process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 10
13 or 1014 viral RNA copy per dose) of OZG-38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efficacy of the vaccine. Human ACE2-encoding transgenic mice were immunized and then infected with the SARS-CoV-2 virus for the challenge test. This study shows that vaccinated mice have lowered SARS-CoV-2 viral RNA copy numbers both in oropharyngeal specimens and in the histological analysis of the lung tissues along with humoral and cellular immune responses, including the neutralizing antibodies similar to those shown in BALB/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
5. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.
- Author
-
Sir Karakus G, Tastan C, Dilek Kancagi D, Yurtsever B, Tumentemur G, Demir S, Turan RD, Abanuz S, Cakirsoy D, Seyis U, Ozer S, Elibol O, Elek M, Ertop G, Arbak S, Acikel Elmas M, Hemsinlioglu C, Kocagoz AS, Hatirnaz Ng O, Akyoney S, Sahin I, Ozbek U, Telci D, Sahin F, Yalcin K, Ratip S, and Ovali E
- Subjects
- Animals, COVID-19 Vaccines toxicity, Female, Gamma Rays, Genome, Viral, Humans, Male, Mice, Inbred BALB C, SARS-CoV-2 genetics, Vaccines, Inactivated toxicity, Mice, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, Vaccines, Inactivated immunology
- Abstract
COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2 + mice.
- Published
- 2021
- Full Text
- View/download PDF
6. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer.
- Author
-
Einav U, Tabach Y, Getz G, Yitzhaky A, Ozbek U, Amariglio N, Izraeli S, Rechavi G, and Domany E
- Subjects
- Base Sequence, Child, DNA Primers, Female, Humans, Polymerase Chain Reaction, Breast Neoplasms genetics, Gene Expression Profiling, Interferons physiology, Ovarian Neoplasms genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
On the basis of epidemiological studies, infection was suggested to play a role in the etiology of human cancer. While for some cancers such a role was indeed demonstrated, there is no direct biological support for the role of viral pathogens in the pathogenesis of childhood leukemia. Using a novel bioinformatic tool that alternates between clustering and standard statistical methods of analysis, we performed a 'double-blind' search of published gene expression data of subjects with different childhood acute lymphoblastic leukemia (ALL) subtypes, looking for unanticipated partitions of patients, induced by unexpected groups of genes with correlated expression. We discovered a group of about 30 genes, related to the interferon response pathway, whose expression levels divide the ALL samples into two subgroups; high in 50, low in 285 patients. Leukemic subclasses prevalent in early childhood (the age most susceptible to infection) are over-represented in the high-expression subgroup. Similar partitions, induced by the same genes, were found also in breast and ovarian cancer but not in lung cancer, prostate cancer and lymphoma. About 40% of breast cancer samples expressed the 'interferon-related' signature. It is of interest that several studies demonstrated mouse mammary tumor virus-like sequences in about 40% of breast cancer samples. Our discovery of an unanticipated strong signature of an interferon-induced pathway provides molecular support for a role for either inflammation or viral infection in the pathogenesis of childhood leukemia as well as breast and ovarian cancer.
- Published
- 2005
- Full Text
- View/download PDF
7. Real-Time PCR analysis of af4 and dek genes expression in acute promyelocytic leukemia t (15;17) patients.
- Author
-
Savli H, Sirma S, Nagy B, Aktan M, Dincol G, Salcioglu Z, Sarper N, and Ozbek U
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Chromosomal Proteins, Non-Histone metabolism, Chromosomes, Human, Pair 15, Chromosomes, Human, Pair 17, DNA-Binding Proteins metabolism, Down-Regulation, Female, Gene Expression, Humans, Leukemia, Promyelocytic, Acute metabolism, Male, Middle Aged, Nuclear Proteins metabolism, Oncogene Proteins metabolism, Poly-ADP-Ribose Binding Proteins, Polymerase Chain Reaction, RNA, Messenger analysis, RNA, Messenger metabolism, Transcriptional Elongation Factors, Translocation, Genetic, Up-Regulation, Chromosomal Proteins, Non-Histone genetics, DNA-Binding Proteins genetics, Leukemia, Promyelocytic, Acute genetics, Nuclear Proteins genetics, Oncogene Proteins genetics
- Abstract
Among several newly identified oncogenes, dek and af4 are attractive targets for researchers interested with leukemia. In this study quantitative Real-Time RT-PCR technique was used to define alterations in expression of dek and af4 genes associated with acute promyelocytic leukaemia (APL) t (15; 17). RNA samples obtained from bone marrow aspirates of fourteen APL patients, cDNA portions were labelled with Syber Green 1 dye and LightCycler analysis have been performed. Expression changes in patients were found not significant in comparison to healthy donors for af4 (P = 0.192) and dek (P = 0.0895). We suggest that af4 gene may have a role in leukomogenesis restricted to lymphoblastic lineage; also further studies must carry on with a larger series of patients in order to understand the relationship between the dek gene and APL. Our study was the first attempt for analysing dek and af4 genes in APL t (15; 17) patients by quantitative Real-Time RT-PCR. This rapid and sensitive method could be used to screen these genes in different types of leukaemia.
- Published
- 2004
- Full Text
- View/download PDF
8. Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients.
- Author
-
Savli H, Sirma S, Nagy B, Aktan M, Dincol G, and Ozbek U
- Subjects
- Apoptosis drug effects, Chromosomes, Human, Pair 15 genetics, Chromosomes, Human, Pair 17 genetics, Gene Expression Profiling, HL-60 Cells, Humans, Time Factors, Apoptosis genetics, Gene Expression Regulation, Neoplastic drug effects, Leukemia, Promyelocytic, Acute genetics, Polymerase Chain Reaction methods, Translocation, Genetic genetics, Tretinoin pharmacology
- Abstract
All-trans retinoic acid (ATRA) treatment of the acute promyelocytic leukemia (APL) have subsequently resulted in cell apoptosis, but the molecular mechanism of this effect remains elusive. In order to understand a possible involvement of genes regulating apoptotic signal pathways, expression levels of bcl2, bax, dapk1, myc, bad, wt1, and mcl genes were analyzed during ATRA treatment in five APL patients with t (15;17) using Real- time PCR (LightCycler). Two samples from each patient were compared to each other: primary diagnostic sample and a sample taken at remission. Effect of the ATRA treatment was demonstrated by the concomitant induction of cd14 and il1beta genes in four patients. Also other apoptosis related genes were found down-regulated in general but especially the down regulated levels of wt1 and bax attract attention. Result suggested that ATRA dependent apoptosis of APL was under the control of both internal and external pathways without relationships to the amount of the blast populations. Ratio of bcl2 to bax may be more important for this regulation than the ratio of bcl2 to bad. Either bcl2 family or less known apoptosis related genes as wt1 will still be required to further studies in this setting.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.